Status:
UNKNOWN
A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia
Lead Sponsor:
Central South University
Conditions:
Impaired Cognition
Schizophrenia
Eligibility:
All Genders
18-40 years
Phase:
PHASE4
Brief Summary
The objective of the study was to study the effects of donepezil on cognition in patients with schizophrenia. The investigators conducted a 12-week, double-blind, placebo-controlled trial of donepezil...
Detailed Description
The investigators conducted a 12-week, double-blind, placebo-controlled trial of donepezil as adjunctive treatment to antipsychotic drugs on patients with schizophrenia.The trial will be complete in 2...
Eligibility Criteria
Inclusion
- DSM-IV diagnosis of schizophrenia as determined by the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version;
- Between 18 and 40 years of age;
- Duration of the illness must be longer than 2 year;
- Patient's current antipsychotic medication regimen must be stable;
- Must be in a stable living arrangement;
Exclusion
- Patient has mental retardation or severe organic brain syndromes;
- Treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening;
- Has suicidal attempts or ideation or violent behavior within the last 12 months;
- Patient has a history of alcohol/drug dependence;
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01490567
Start Date
June 1 2011
End Date
June 1 2012
Last Update
December 13 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the Second Xiangya Hospital of Central South University
Changsha, Hunan, China, 410011